Kidney Transplant Market to Reach US$ 10.99 Billion by 2033 | CAGR 3.7% | North America Leads with 38% Share | Key Players: Transonic, Sanofi, Organ Recovery Systems, Pfizer, TransMedics

Kidney Transplant Market

The global kidney transplant market reached US$ 7.91 billion in 2024 and is projected to grow to US$ 10.99 billion by 2033, registering a CAGR of 3.7% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/kidney-transplant-market?Juli

The market growth is primarily driven by the rising prevalence of end-stage renal disease (ESRD) and chronic kidney disorders worldwide. Advances in surgical techniques, immunosuppressive therapies, and organ preservation technologies have improved transplant success rates and patient outcomes, supporting market expansion. Furthermore, increasing awareness of organ donation, favorable government policies, and higher healthcare investments are facilitating greater access to kidney transplantation. Initiatives promoting organ donation registration, donor-recipient matching programs, and reimbursement frameworks are further propelling growth in both developed and emerging markets.

Recent Developments:

✅ January 2026: A leading transplant center implemented robot-assisted kidney transplant surgeries, enhancing precision, reducing operative time, and improving post-operative recovery for patients.

✅ November 2025: A global biotech firm announced successful clinical trials for a new immunosuppressive therapy aimed at reducing graft rejection rates in kidney transplant recipients.

✅ September 2025: A healthcare technology company launched an AI-powered organ matching platform that optimizes donor-recipient compatibility and reduces waiting times for transplant patients.

✅ June 2025: A consortium of hospitals partnered with a telehealth provider to enable remote post-transplant monitoring, improving patient adherence to medication and follow-up protocols.

✅ March 2025: A medical device manufacturer introduced next-generation perfusion and organ preservation systems to improve kidney viability during transport and reduce transplant complications.

Mergers & Acquisitions

✅ January 2026: A major renal care provider acquired a specialized organ preservation solutions company, expanding its portfolio in transplant-support technologies.

✅ October 2025: A leading pharmaceutical firm completed the acquisition of a biotech startup focused on immunosuppressive drugs, strengthening its pipeline for kidney transplant therapeutics.

✅ August 2025: A healthcare technology company merged with a digital patient monitoring platform, integrating AI-driven analytics for post-transplant care management.

✅ May 2025: A global medical device manufacturer acquired a kidney transplant surgical tools supplier, enhancing its offerings for operating rooms and transplant centers.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=kidney-transplant-market?Juli

Key Players:

• Transonic - Holds a 12.3% share, driven by its advanced hemodynamic monitoring and organ perfusion systems that enhance transplant success rates.

• Sanofi S.A. - Holds a 11.8% share, fueled by its portfolio of immunosuppressive therapies and post-transplant patient care solutions.

• Organ Recovery Systems, Inc. - Holds a 10.5% share, supported by its organ preservation and perfusion technologies that improve organ viability during transport.

• Pfizer Inc. - Holds a 10.0% share, backed by its biologics and immunosuppressive drugs used in transplant patient management.

• TransMedics Inc. - Holds a 9.4% share, driven by its innovative ex vivo organ perfusion systems that extend organ preservation time.

• Novartis AG - Holds an 8.7% share, strengthened by its immunosuppressant therapies and post-transplant patient support programs.

• Preservation Solutions Inc. - Holds a 7.9% share, focused on cold storage and preservation solutions for kidney and other organ transplants.

• B. Braun Melsungen AG - Holds a 7.3% share, fueled by dialysis, perfusion, and surgical support devices used in transplant centers.

• Medtronic plc - Holds a 6.8% share, supported by its advanced surgical tools and organ perfusion systems for transplant procedures.

• Fresenius Medical Care AG & Co. - Holds a 5.9% share, backed by its dialysis and transplant support solutions that improve patient outcomes.

Market Segmentation:

By Product Type
Preservation and Storage Devices - 32%, driven by increasing demand for advanced organ preservation technologies that extend kidney viability and reduce graft rejection rates.

Surgical Equipment - 28%, supported by the adoption of minimally invasive and robotic-assisted transplant procedures that improve patient outcomes.

Dialysis Equipment - 20%, fueled by the integration of pre- and post-transplant dialysis solutions to maintain patient health and readiness for transplantation.

Other Consumables - 20%, including surgical disposables, perfusion solutions, and immunosuppressive therapy administration tools.

By Transplant Type
Living Donor Transplant - 45%, due to higher survival rates, improved organ compatibility, and increasing public awareness campaigns.

Paired Kidney Transplant - 25%, driven by organ swap programs and registries facilitating transplants among incompatible donor-recipient pairs.

Deceased Donor Transplant - 30%, supported by organ donation drives, regulatory frameworks, and advanced organ preservation systems.

By Preservation Method
Hypothermic Machine Perfusion (HMP) - 38%, benefiting from enhanced organ viability and better post-transplant outcomes compared to static methods.

Static Cold Storage (SCS) - 35%, still widely used due to simplicity, cost-effectiveness, and established clinical protocols.

Normothermic Machine Perfusion (NMP) - 20%, growing rapidly with technological advancements that allow real-time organ assessment before transplant.

Others - 7%, including hybrid and emerging preservation techniques under research or pilot stages.

By Age Group
Children - 12%, driven by pediatric transplant programs and specialized surgical equipment for young patients.

Adults - 68%, representing the majority of transplant recipients due to higher ESRD prevalence in this population.

Geriatrics - 20%, increasing with the aging population and improved transplant survival among older patients.

By End-User
Hospitals - 40%, as major transplant procedures and post-operative care are primarily performed in hospital settings.

Specialty Clinics - 25%, focusing on pre- and post-transplant care, dialysis, and outpatient monitoring.

Transplant Centers - 35%, benefiting from dedicated organ transplant infrastructure, surgical expertise, and high patient volumes.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/kidney-transplant-market?Juli

Regional Insights:

North America - 38%
North America dominates the kidney transplant market due to advanced healthcare infrastructure, widespread organ donation programs, and well-established transplant centers. The U.S. leads with a high prevalence of end-stage renal disease (ESRD) and strong government support through initiatives like the Organ Procurement and Transplantation Network (OPTN) and KidneyX. Technological adoption, such as AI-driven organ matching and advanced preservation devices, further strengthens market growth in the region.

Europe - 28%
Europe holds a significant share of the kidney transplant market, supported by robust public healthcare systems, standardized organ allocation policies, and rising awareness of organ donation. Countries like Germany, France, and the UK have advanced surgical facilities and transplant networks, which increase transplant success rates. The market growth is also bolstered by government programs incentivizing living donations and organ preservation research.

Asia-Pacific - 22%
Asia-Pacific is witnessing rapid growth in kidney transplants, driven by increasing ESRD prevalence, improving healthcare infrastructure, and rising investments in specialty transplant centers. India, China, Japan, and South Korea are key contributors, with government initiatives promoting organ donation awareness and expanding access to advanced surgical and preservation technologies. The region's growth is further accelerated by a large patient population and rising disposable income supporting access to high-quality care.

Market Dynamics:

Driver:
The global kidney transplant market is primarily driven by the increasing prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD), fueled by aging populations, lifestyle-related disorders, obesity, and diabetes. These conditions often lead to irreversible kidney damage, creating a growing need for renal replacement therapies, including dialysis and kidney transplantation. Kidney transplants offer superior long-term outcomes and quality of life compared to alternative treatments, making them the preferred solution for eligible patients.

Advancements in surgical techniques, immunosuppressive therapies, and organ preservation technologies, coupled with growing awareness of organ donation, further support market growth. For example, the United States Renal Data System 2024 Annual Data Report indicates that over 808,000 people in the U.S. are living with ESRD, with 68% on dialysis and 32% having undergone kidney transplantation. Males are 1.6 times more likely to develop ESRD than females. Black individuals are over 4 times more likely, and Hispanic and Native American populations are more than twice as likely to develop ESRD compared to White populations. The prevalence among Asian populations is 1.6 times higher, with minority populations experiencing a tripling in kidney failure cases since 2001.

Restraint:
The high cost of kidney transplantation remains a major restraint, limiting access for many patients, especially in low- and middle-income countries. The procedure encompasses pre-operative evaluations, surgical fees, hospitalization, and post-transplant care, often resulting in expenses that are not fully covered by insurance or government programs. This financial barrier contributes to disparities in access, forcing many patients to rely on dialysis or other less effective treatments.

For instance, the average cost of a kidney transplant is approximately $442,500, with admission charges accounting for 34% of the total. Despite rising medication costs, only 7% of expenses are allocated to immunosuppressive and transplant-related drugs, including prophylactic antibiotics, highlighting the significant financial burden on patients.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.